Is Retatrutide Stronger Than Tirzepatide? The Trial Evidence So Far

What the phase 2 retatrutide data actually showed

The trial that put retatrutide on the map was a phase 2, dose-ranging study published in the New England Journal of Medicine in 2023. It randomised 338 adults with obesity across several doses of retatrutide and placebo. At the highest dose tested (12 mg), participants lost an average of around 17.5% of body weight over 24 weeks and, when projected to 48 weeks, some analyses pointed toward reductions approaching 24%. Those are striking numbers.

The mechanism behind them matters. Retatrutide acts on three receptors (GIP, GLP-1 and glucagon) whereas tirzepatide activates GIP and GLP-1 only. The glucagon component is thought to increase energy expenditure and promote fat breakdown, not just reduce appetite. That extra pathway may explain part of the difference in the early data.

Phase 2 trials are designed to establish dosing and safety signals, not to confirm efficacy at scale. The retatrutide study involved a few hundred participants over less than a year. Tirzepatide's SURMOUNT-1 trial, by contrast, followed 2,539 adults for 72 weeks, a substantially larger and longer dataset that underpins the NICE appraisal of tirzepatide (TA1026). Comparing the two sets of numbers directly, as if they came from equivalent trials, overstates what we know about retatrutide.

One important caveat: phase 3 retatrutide trials are under way, and the picture may sharpen considerably over the next two to three years.

What 'stronger' might mean, and why it is not the only question

A question our prescribers hear most weeks is some version of: "If retatrutide is more effective, why isn't anyone prescribing it?" The answer is straightforward. A medicine needs to complete large-scale phase 3 trials, demonstrate a satisfactory safety profile across thousands of participants over at least a year, and then receive regulatory approval before any prescriber can lawfully use it. Retatrutide has not reached that stage.

Efficacy is also only one dimension of comparison. The side-effect profile of retatrutide at higher doses included more pronounced gastrointestinal symptoms and, because the glucagon pathway raises heart rate, some participants showed modest pulse increases. Whether those effects are clinically meaningful at population scale is precisely what phase 3 studies are designed to establish. For a fuller look at how the two compounds sit against each other across multiple dimensions, the retatrutide versus tirzepatide effectiveness page covers the evidence in more depth.

Tirzepatide's real-world standing, by contrast, is well evidenced. SURMOUNT-1 showed around 20–21% average body-weight reduction at 15 mg, with NICE recommending it for adults meeting BMI and comorbidity thresholds. That recommendation rests on a full dossier of phase 3 data, not a single phase 2 signal. When thinking about cost alongside potential access in future, our cost comparison page sets out what is known.

The UK licensing reality and what it means for anyone considering weight management treatment now

In the UK, only medicines holding a valid MHRA authorisation may be prescribed for a given indication. Retatrutide has none. That is not a technicality, it reflects the absence of the safety and efficacy evidence base the regulator requires before approving any medicine for public use. Any source claiming to supply retatrutide as a weight-loss treatment in the UK right now should be treated with serious scepticism; there is no licensed product, which means no regulated supply chain, no approved dose, and no manufacturer standing behind the quality of what is being sold.

Tirzepatide, on the other hand, is manufactured by Eli Lilly through an authorised supply chain, dispensed under prescription by GPhC-registered pharmacies, and subject to ongoing MHRA safety monitoring. It carries a Black Triangle (▼) designation, meaning the regulator collects additional data on its real-world use. If you are interested in what UK-licensed weight management treatment looks like right now, the tirzepatide overview covers the clinical picture in plain terms.

It is also worth being clear about what "stronger" means for an individual. Average trial outcomes are population statistics. A person's response depends on their biology, their starting weight, how they tolerate each dose step, and whether they can sustain the lifestyle changes that accompany treatment. A medicine showing a higher average in a phase 2 trial tells you something useful about mechanism, but it does not tell you what you, specifically, would experience, and no prescriber can make that prediction with certainty either.

For a broader look at how retatrutide relates to the current Mounjaro landscape, our retatrutide and Mounjaro page explains where the research sits and what the development timeline looks like. And if questions about combining or switching treatments have crossed your mind, mixing tirzepatide and retatrutide addresses that directly, the short answer being that it is not something any licensed prescriber can currently oversee.

If you are ready to explore what licensed weight management treatment could look like for you through a regulated UK pharmacy, check your eligibility with our prescribers. Every consultation is assessed by a GPhC-registered Independent Prescriber, not an automated system. There are no subscriptions and no hidden fees.